Research
Hormonal
Obesity, particularly central/visceral obesity, is a primary cause of insulin resistance through mechanisms involving increased free fatty acids, chronic inflammation, and adipokine dysregulation.
Losing even a modest amount of weight (e.g., 10% of body weight) can significantly improve insulin sensitivity, especially if the weight is visceral fat. Focus on reducing abdominal fat through caloric deficit and exercise, as this directly addresses the root cause of obesity-induced insulin resistance.
GoodSupportsHIGH confidence
Obesity, especially central obesity, may induce the development of IR due to the massive accumulation of adipose tissue inducing systemic insulin resistance, including endocrine dysregulation and inflammation.
Why this rating
Supported by multiple citations and mechanistic explanations in the review.
Source
The crucial role and mechanism of insulin resistance in metabolic disease
Xuefei Zhao et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1149239
narrative_reviewCited 505×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin resistance (IR) is a central pathophysiological mechanism that drives the development and progression of multiple metabolic diseases, including type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease (NAFLD), and certain cancers.Good
- Chronic low-grade inflammation, driven by obesity and characterized by elevated pro-inflammatory cytokines (TNF-alpha, IL-6, CRP), directly interferes with insulin signaling pathways, contributing to insulin resistance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →